#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The World Health Organisation recommends exclusive breastfeeding for infants up to six months of age , based on the clear health benefits of breastfeeding on mother-infant dyad .
2-1	16-19	The	organization[2]	new[2]	_	_
2-2	20-25	World	organization[2]	new[2]	_	_
2-3	26-32	Health	organization[2]	new[2]	_	_
2-4	33-45	Organisation	organization[2]	new[2]	_	_
2-5	46-56	recommends	_	_	_	_
2-6	57-66	exclusive	_	_	_	_
2-7	67-80	breastfeeding	_	_	_	_
2-8	81-84	for	_	_	_	_
2-9	85-92	infants	person[3]	new[3]	coref	4-1[0_3]
2-10	93-95	up	person[3]	new[3]	_	_
2-11	96-98	to	_	_	_	_
2-12	99-102	six	time[4]	new[4]	coref	6-29[35_4]
2-13	103-109	months	time[4]	new[4]	_	_
2-14	110-112	of	time[4]	new[4]	_	_
2-15	113-116	age	time[4]|abstract	new[4]|new	_	_
2-16	117-118	,	_	_	_	_
2-17	119-124	based	_	_	_	_
2-18	125-127	on	_	_	_	_
2-19	128-131	the	abstract[7]	new[7]	coref	6-2[28_7]
2-20	132-137	clear	abstract[7]	new[7]	_	_
2-21	138-144	health	abstract|abstract[7]	new|new[7]	_	_
2-22	145-153	benefits	abstract[7]	new[7]	_	_
2-23	154-156	of	_	_	_	_
2-24	157-170	breastfeeding	_	_	_	_
2-25	171-173	on	_	_	_	_
2-26	174-187	mother-infant	abstract[8]	new[8]	coref	15-19[124_8]
2-27	188-192	dyad	abstract[8]	new[8]	_	_
2-28	193-194	.	_	_	_	_

#Text=Indeed , there is a consensus regarding the association of breastfeeding with a reduced risk of respiratory and gastro-intestinal infections during the first year of life .
3-1	195-201	Indeed	_	_	_	_
3-2	202-203	,	_	_	_	_
3-3	204-209	there	_	_	_	_
3-4	210-212	is	_	_	_	_
3-5	213-214	a	abstract[9]	new[9]	_	_
3-6	215-224	consensus	abstract[9]	new[9]	_	_
3-7	225-234	regarding	_	_	_	_
3-8	235-238	the	abstract[10]	new[10]	_	_
3-9	239-250	association	abstract[10]	new[10]	_	_
3-10	251-253	of	_	_	_	_
3-11	254-267	breastfeeding	_	_	_	_
3-12	268-272	with	_	_	_	_
3-13	273-274	a	abstract[11]	new[11]	coref	4-13[17_11]
3-14	275-282	reduced	abstract[11]	new[11]	_	_
3-15	283-287	risk	abstract[11]	new[11]	_	_
3-16	288-290	of	abstract[11]	new[11]	_	_
3-17	291-302	respiratory	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-18	303-306	and	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-19	307-324	gastro-intestinal	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-20	325-335	infections	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-21	336-342	during	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-22	343-346	the	abstract[11]|abstract[12]|time[13]	new[11]|new[12]|new[13]	_	_
3-23	347-352	first	abstract[11]|abstract[12]|time[13]	new[11]|new[12]|new[13]	_	_
3-24	353-357	year	abstract[11]|abstract[12]|time[13]	new[11]|new[12]|new[13]	_	_
3-25	358-360	of	abstract[11]|abstract[12]|time[13]	new[11]|new[12]|new[13]	_	_
3-26	361-365	life	abstract[11]|abstract[12]|time[13]|abstract	new[11]|new[12]|new[13]|new	_	_
3-27	366-367	.	_	_	_	_

#Text=Infants , who were breastfed for longer periods , may also have a lower risk of developing obesity and type II diabetes at adulthood .
4-1	368-375	Infants	person	giv	_	_
4-2	376-377	,	_	_	_	_
4-3	378-381	who	_	_	_	_
4-4	382-386	were	_	_	_	_
4-5	387-396	breastfed	_	_	_	_
4-6	397-400	for	_	_	_	_
4-7	401-407	longer	time[16]	new[16]	_	_
4-8	408-415	periods	time[16]	new[16]	_	_
4-9	416-417	,	_	_	_	_
4-10	418-421	may	_	_	_	_
4-11	422-426	also	_	_	_	_
4-12	427-431	have	_	_	_	_
4-13	432-433	a	abstract[17]	giv[17]	coref	5-7[23_17]
4-14	434-439	lower	abstract[17]	giv[17]	_	_
4-15	440-444	risk	abstract[17]	giv[17]	_	_
4-16	445-447	of	_	_	_	_
4-17	448-458	developing	_	_	_	_
4-18	459-466	obesity	abstract	new	_	_
4-19	467-470	and	_	_	_	_
4-20	471-475	type	object	new	coref	5-14
4-21	476-478	II	abstract[20]	new[20]	coref	5-15[27_20]
4-22	479-487	diabetes	abstract[20]	new[20]	_	_
4-23	488-490	at	abstract[20]	new[20]	_	_
4-24	491-500	adulthood	abstract[20]|abstract	new[20]|new	_	_
4-25	501-502	.	_	_	_	_

#Text=For mothers , breastfeeding could limit the risk of developing ovarian cancer and type II diabetes .
5-1	503-506	For	_	_	_	_
5-2	507-514	mothers	person	new	coref	6-27
5-3	515-516	,	_	_	_	_
5-4	517-530	breastfeeding	_	_	_	_
5-5	531-536	could	_	_	_	_
5-6	537-542	limit	_	_	_	_
5-7	543-546	the	abstract[23]	giv[23]	_	_
5-8	547-551	risk	abstract[23]	giv[23]	_	_
5-9	552-554	of	_	_	_	_
5-10	555-565	developing	_	_	_	_
5-11	566-573	ovarian	person|abstract[25]	new|new[25]	_	_
5-12	574-580	cancer	abstract[25]	new[25]	_	_
5-13	581-584	and	_	_	_	_
5-14	585-589	type	object	giv	_	_
5-15	590-592	II	abstract[27]	giv[27]	coref	19-15[145_27]
5-16	593-601	diabetes	abstract[27]	giv[27]	_	_
5-17	602-603	.	_	_	_	_

#Text=Despite these benefits , breastfeeding prevalence remains relatively low , particularly in several high-income countries in North America and Europe , where only 40 % of mothers breastfeed six months after delivery .
6-1	604-611	Despite	_	_	_	_
6-2	612-617	these	abstract[28]	giv[28]	_	_
6-3	618-626	benefits	abstract[28]	giv[28]	_	_
6-4	627-628	,	_	_	_	_
6-5	629-642	breastfeeding	abstract[29]	new[29]	_	_
6-6	643-653	prevalence	abstract[29]	new[29]	_	_
6-7	654-661	remains	_	_	_	_
6-8	662-672	relatively	_	_	_	_
6-9	673-676	low	_	_	_	_
6-10	677-678	,	_	_	_	_
6-11	679-691	particularly	place[30]	new[30]	coref	7-12[41_30]
6-12	692-694	in	place[30]	new[30]	_	_
6-13	695-702	several	place[30]	new[30]	_	_
6-14	703-714	high-income	place[30]	new[30]	_	_
6-15	715-724	countries	place[30]	new[30]	_	_
6-16	725-727	in	place[30]	new[30]	_	_
6-17	728-733	North	place[30]|place[31]	new[30]|new[31]	_	_
6-18	734-741	America	place[30]|place[31]	new[30]|new[31]	_	_
6-19	742-745	and	place[30]	new[30]	_	_
6-20	746-752	Europe	place[30]|place	new[30]|new	_	_
6-21	753-754	,	_	_	_	_
6-22	755-760	where	_	_	_	_
6-23	761-765	only	quantity[33]	new[33]	_	_
6-24	766-768	40	quantity[33]	new[33]	_	_
6-25	769-770	%	quantity[33]	new[33]	_	_
6-26	771-773	of	quantity[33]	new[33]	_	_
6-27	774-781	mothers	quantity[33]|person	new[33]|giv	coref	13-17[104_0]
6-28	782-792	breastfeed	_	_	_	_
6-29	793-796	six	time[35]	giv[35]	_	_
6-30	797-803	months	time[35]	giv[35]	_	_
6-31	804-809	after	_	_	_	_
6-32	810-818	delivery	event	new	_	_
6-33	819-820	.	_	_	_	_

#Text=Exclusive breastfeeding rate is about 60 % at four months in Scandinavian countries , 35 % in the Netherlands , 16 % in the UK , and 10 % in France .
7-1	821-830	Exclusive	quantity[38]	new[38]	coref	7-5[39_38]
7-2	831-844	breastfeeding	abstract|quantity[38]	new|new[38]	_	_
7-3	845-849	rate	quantity[38]	new[38]	_	_
7-4	850-852	is	_	_	_	_
7-5	853-858	about	quantity[39]	giv[39]	_	_
7-6	859-861	60	quantity[39]	giv[39]	_	_
7-7	862-863	%	quantity[39]	giv[39]	_	_
7-8	864-866	at	quantity[39]	giv[39]	_	_
7-9	867-871	four	quantity[39]|time[40]	giv[39]|new[40]	_	_
7-10	872-878	months	quantity[39]|time[40]	giv[39]|new[40]	_	_
7-11	879-881	in	quantity[39]|time[40]	giv[39]|new[40]	_	_
7-12	882-894	Scandinavian	quantity[39]|time[40]|place[41]	giv[39]|new[40]|giv[41]	coref	19-7[142_41]
7-13	895-904	countries	quantity[39]|time[40]|place[41]	giv[39]|new[40]|giv[41]	_	_
7-14	905-906	,	quantity[39]	giv[39]	_	_
7-15	907-909	35	quantity[39]|quantity[42]	giv[39]|new[42]	coref	9-31[60_42]
7-16	910-911	%	quantity[39]|quantity[42]	giv[39]|new[42]	_	_
7-17	912-914	in	quantity[39]|quantity[42]	giv[39]|new[42]	_	_
7-18	915-918	the	quantity[39]|quantity[42]|place[43]	giv[39]|new[42]|new[43]	_	_
7-19	919-930	Netherlands	quantity[39]|quantity[42]|place[43]	giv[39]|new[42]|new[43]	_	_
7-20	931-932	,	quantity[39]	giv[39]	_	_
7-21	933-935	16	quantity[39]|quantity[44]	giv[39]|new[44]	_	_
7-22	936-937	%	quantity[39]|quantity[44]	giv[39]|new[44]	_	_
7-23	938-940	in	quantity[39]|quantity[44]	giv[39]|new[44]	_	_
7-24	941-944	the	quantity[39]|quantity[44]|place[45]	giv[39]|new[44]|new[45]	_	_
7-25	945-947	UK	quantity[39]|quantity[44]|place[45]	giv[39]|new[44]|new[45]	_	_
7-26	948-949	,	quantity[39]	giv[39]	_	_
7-27	950-953	and	quantity[39]	giv[39]	_	_
7-28	954-956	10	quantity[39]|quantity[46]	giv[39]|new[46]	_	_
7-29	957-958	%	quantity[39]|quantity[46]	giv[39]|new[46]	_	_
7-30	959-961	in	quantity[39]|quantity[46]	giv[39]|new[46]	_	_
7-31	962-968	France	quantity[39]|quantity[46]|place	giv[39]|new[46]|new	_	_
7-32	969-970	.	_	_	_	_

#Text=Early cessation of breastfeeding clearly is multifactorial .
8-1	971-976	Early	event[48]	new[48]	coref	9-26[59_48]
8-2	977-986	cessation	event[48]	new[48]	_	_
8-3	987-989	of	event[48]	new[48]	_	_
8-4	990-1003	breastfeeding	event[48]|person	new[48]|new	_	_
8-5	1004-1011	clearly	_	_	_	_
8-6	1012-1014	is	_	_	_	_
8-7	1015-1029	multifactorial	_	_	_	_
8-8	1030-1031	.	_	_	_	_

#Text=One of the main factors is the maternal perception of insufficient milk secretion to quell infant ’s hunger or support infant growth and leads to early cessation of breastfeeding in 35 % of cases .
9-1	1032-1035	One	abstract[50]	new[50]	coref	9-7[52_50]
9-2	1036-1038	of	abstract[50]	new[50]	_	_
9-3	1039-1042	the	abstract[50]|abstract[51]	new[50]|new[51]	_	_
9-4	1043-1047	main	abstract[50]|abstract[51]	new[50]|new[51]	_	_
9-5	1048-1055	factors	abstract[50]|abstract[51]	new[50]|new[51]	_	_
9-6	1056-1058	is	_	_	_	_
9-7	1059-1062	the	abstract[52]	giv[52]	_	_
9-8	1063-1071	maternal	abstract[52]	giv[52]	_	_
9-9	1072-1082	perception	abstract[52]	giv[52]	_	_
9-10	1083-1085	of	abstract[52]	giv[52]	_	_
9-11	1086-1098	insufficient	abstract[52]|substance[54]	giv[52]|new[54]	coref	10-29[69_54]
9-12	1099-1103	milk	abstract[52]|substance|substance[54]	giv[52]|new|new[54]	coref	10-4
9-13	1104-1113	secretion	abstract[52]|substance[54]	giv[52]|new[54]	_	_
9-14	1114-1116	to	_	_	_	_
9-15	1117-1122	quell	_	_	_	_
9-16	1123-1129	infant	person[55]|event[56]	new[55]|new[56]	coref|ana	9-21[0_55]|10-24[0_56]
9-17	1130-1132	’s	person[55]|event[56]	new[55]|new[56]	_	_
9-18	1133-1139	hunger	event[56]	new[56]	_	_
9-19	1140-1142	or	_	_	_	_
9-20	1143-1150	support	abstract[58]	new[58]	_	_
9-21	1151-1157	infant	person|abstract[58]	giv|new[58]	coref	12-45[98_0]
9-22	1158-1164	growth	abstract[58]	new[58]	_	_
9-23	1165-1168	and	_	_	_	_
9-24	1169-1174	leads	_	_	_	_
9-25	1175-1177	to	_	_	_	_
9-26	1178-1183	early	event[59]	giv[59]	_	_
9-27	1184-1193	cessation	event[59]	giv[59]	_	_
9-28	1194-1196	of	event[59]	giv[59]	_	_
9-29	1197-1210	breastfeeding	event[59]	giv[59]	_	_
9-30	1211-1213	in	_	_	_	_
9-31	1214-1216	35	quantity[60]	giv[60]	_	_
9-32	1217-1218	%	quantity[60]	giv[60]	_	_
9-33	1219-1221	of	quantity[60]	giv[60]	_	_
9-34	1222-1227	cases	quantity[60]|abstract	giv[60]|new	_	_
9-35	1228-1229	.	_	_	_	_

#Text=Perception of insufficient milk production is a complex , multifactorial issue that can have biological , social , or psychological determinants , and it often remains unclear whether the low milk secretion is real or only perceived .
10-1	1230-1240	Perception	abstract[62]	new[62]	coref	10-7[65_62]
10-2	1241-1243	of	abstract[62]	new[62]	_	_
10-3	1244-1256	insufficient	abstract[62]|abstract[64]	new[62]|new[64]	coref	11-14[74_64]
10-4	1257-1261	milk	abstract[62]|substance|abstract[64]	new[62]|giv|new[64]	coref	10-31
10-5	1262-1272	production	abstract[62]|abstract[64]	new[62]|new[64]	_	_
10-6	1273-1275	is	_	_	_	_
10-7	1276-1277	a	abstract[65]	giv[65]	_	_
10-8	1278-1285	complex	abstract[65]	giv[65]	_	_
10-9	1286-1287	,	abstract[65]	giv[65]	_	_
10-10	1288-1302	multifactorial	abstract[65]	giv[65]	_	_
10-11	1303-1308	issue	abstract[65]	giv[65]	_	_
10-12	1309-1313	that	_	_	_	_
10-13	1314-1317	can	_	_	_	_
10-14	1318-1322	have	_	_	_	_
10-15	1323-1333	biological	abstract[66]	new[66]	_	_
10-16	1334-1335	,	abstract[66]	new[66]	_	_
10-17	1336-1342	social	abstract[66]	new[66]	_	_
10-18	1343-1344	,	abstract[66]	new[66]	_	_
10-19	1345-1347	or	abstract[66]	new[66]	_	_
10-20	1348-1361	psychological	abstract[66]	new[66]	_	_
10-21	1362-1374	determinants	abstract[66]	new[66]	_	_
10-22	1375-1376	,	_	_	_	_
10-23	1377-1380	and	_	_	_	_
10-24	1381-1383	it	event	giv	_	_
10-25	1384-1389	often	_	_	_	_
10-26	1390-1397	remains	_	_	_	_
10-27	1398-1405	unclear	_	_	_	_
10-28	1406-1413	whether	_	_	_	_
10-29	1414-1417	the	substance[69]	giv[69]	coref	12-1[82_69]
10-30	1418-1421	low	substance[69]	giv[69]	_	_
10-31	1422-1426	milk	substance|substance[69]	giv|giv[69]	coref	11-15
10-32	1427-1436	secretion	substance[69]	giv[69]	_	_
10-33	1437-1439	is	_	_	_	_
10-34	1440-1444	real	_	_	_	_
10-35	1445-1447	or	_	_	_	_
10-36	1448-1452	only	_	_	_	_
10-37	1453-1462	perceived	_	_	_	_
10-38	1463-1464	.	_	_	_	_

#Text=Indeed , as a result of the lack of an objective marker of insufficient milk production and the importance of maternal psychology in breastfeeding duration , perceived milk insufficiency is probably much more common than true insufficient production .
11-1	1465-1471	Indeed	_	_	_	_
11-2	1472-1473	,	_	_	_	_
11-3	1474-1476	as	_	_	_	_
11-4	1477-1478	a	_	_	_	_
11-5	1479-1485	result	_	_	_	_
11-6	1486-1488	of	_	_	_	_
11-7	1489-1492	the	abstract[70]	new[70]	_	_
11-8	1493-1497	lack	abstract[70]	new[70]	_	_
11-9	1498-1500	of	abstract[70]	new[70]	_	_
11-10	1501-1503	an	abstract[70]|abstract[72]	new[70]|new[72]	_	_
11-11	1504-1513	objective	abstract[70]|abstract|abstract[72]	new[70]|new|new[72]	coref	26-15[208_0]
11-12	1514-1520	marker	abstract[70]|abstract[72]	new[70]|new[72]	_	_
11-13	1521-1523	of	abstract[70]|abstract[72]	new[70]|new[72]	_	_
11-14	1524-1536	insufficient	abstract[70]|abstract[72]|abstract[74]	new[70]|new[72]|giv[74]	coref	11-36[80_74]
11-15	1537-1541	milk	abstract[70]|abstract[72]|substance|abstract[74]	new[70]|new[72]|giv|giv[74]	coref	11-28
11-16	1542-1552	production	abstract[70]|abstract[72]|abstract[74]	new[70]|new[72]|giv[74]	_	_
11-17	1553-1556	and	abstract[70]	new[70]	_	_
11-18	1557-1560	the	abstract[70]|abstract[75]	new[70]|new[75]	_	_
11-19	1561-1571	importance	abstract[70]|abstract[75]	new[70]|new[75]	_	_
11-20	1572-1574	of	abstract[70]|abstract[75]	new[70]|new[75]	_	_
11-21	1575-1583	maternal	abstract[70]|abstract[75]|abstract[76]	new[70]|new[75]|new[76]	_	_
11-22	1584-1594	psychology	abstract[70]|abstract[75]|abstract[76]	new[70]|new[75]|new[76]	_	_
11-23	1595-1597	in	_	_	_	_
11-24	1598-1611	breastfeeding	_	_	_	_
11-25	1612-1620	duration	time	new	_	_
11-26	1621-1622	,	_	_	_	_
11-27	1623-1632	perceived	_	_	_	_
11-28	1633-1637	milk	substance|abstract[79]	giv|new[79]	coref	12-3
11-29	1638-1651	insufficiency	abstract[79]	new[79]	_	_
11-30	1652-1654	is	_	_	_	_
11-31	1655-1663	probably	_	_	_	_
11-32	1664-1668	much	_	_	_	_
11-33	1669-1673	more	_	_	_	_
11-34	1674-1680	common	_	_	_	_
11-35	1681-1685	than	_	_	_	_
11-36	1686-1690	true	abstract[80]	giv[80]	coref	13-2[101_80]
11-37	1691-1703	insufficient	abstract[80]	giv[80]	_	_
11-38	1704-1714	production	abstract[80]	giv[80]	_	_
11-39	1715-1716	.	_	_	_	_

#Text=True insufficient milk secretion can result from many causes , ranging from inability to lactate due to breast abnormalities or endocrine disorder ( 5 % of women ) to difficulties in breastfeeding management , maternal stress and anxiety , or early food diversification in the infant .
12-1	1717-1721	True	substance[82]	giv[82]	_	_
12-2	1722-1734	insufficient	substance[82]	giv[82]	_	_
12-3	1735-1739	milk	substance|substance[82]	giv|giv[82]	coref	13-3
12-4	1740-1749	secretion	substance[82]	giv[82]	_	_
12-5	1750-1753	can	_	_	_	_
12-6	1754-1760	result	_	_	_	_
12-7	1761-1765	from	_	_	_	_
12-8	1766-1770	many	abstract[83]	new[83]	_	_
12-9	1771-1777	causes	abstract[83]	new[83]	_	_
12-10	1778-1779	,	_	_	_	_
12-11	1780-1787	ranging	_	_	_	_
12-12	1788-1792	from	_	_	_	_
12-13	1793-1802	inability	abstract[84]	new[84]	_	_
12-14	1803-1805	to	abstract[84]	new[84]	_	_
12-15	1806-1813	lactate	abstract[84]|substance[85]	new[84]|new[85]	_	_
12-16	1814-1817	due	abstract[84]|substance[85]	new[84]|new[85]	_	_
12-17	1818-1820	to	_	_	_	_
12-18	1821-1827	breast	place|abstract[87]	new|new[87]	_	_
12-19	1828-1841	abnormalities	abstract[87]	new[87]	_	_
12-20	1842-1844	or	_	_	_	_
12-21	1845-1854	endocrine	abstract[88]	new[88]	_	_
12-22	1855-1863	disorder	abstract[88]	new[88]	_	_
12-23	1864-1865	(	_	_	_	_
12-24	1866-1867	5	quantity[89]	new[89]	coref	22-27[0_89]
12-25	1868-1869	%	quantity[89]	new[89]	_	_
12-26	1870-1872	of	quantity[89]	new[89]	_	_
12-27	1873-1878	women	quantity[89]|person	new[89]|new	_	_
12-28	1879-1880	)	_	_	_	_
12-29	1881-1883	to	_	_	_	_
12-30	1884-1896	difficulties	abstract	new	_	_
12-31	1897-1899	in	_	_	_	_
12-32	1900-1913	breastfeeding	_	_	_	_
12-33	1914-1924	management	person	new	_	_
12-34	1925-1926	,	_	_	_	_
12-35	1927-1935	maternal	abstract|abstract[94]	new|new[94]	coref	13-2
12-36	1936-1942	stress	abstract[94]	new[94]	_	_
12-37	1943-1946	and	_	_	_	_
12-38	1947-1954	anxiety	abstract	new	_	_
12-39	1955-1956	,	_	_	_	_
12-40	1957-1959	or	_	_	_	_
12-41	1960-1965	early	abstract[97]	new[97]	_	_
12-42	1966-1970	food	substance|abstract[97]	new|new[97]	_	_
12-43	1971-1986	diversification	abstract[97]	new[97]	_	_
12-44	1987-1989	in	abstract[97]	new[97]	_	_
12-45	1990-1993	the	abstract[97]|person[98]	new[97]|giv[98]	_	_
12-46	1994-2000	infant	abstract[97]|person[98]	new[97]|giv[98]	_	_
12-47	2001-2002	.	_	_	_	_

#Text=Although maternal milk production can be often increased through psychological support or maternal breastfeeding education , many healthy mothers are eager to enhance their milk production through various nutritional supplements .
13-1	2003-2011	Although	_	_	_	_
13-2	2012-2020	maternal	abstract|abstract[101]	giv|giv[101]	coref	13-24[107_101]
13-3	2021-2025	milk	substance|abstract[101]	giv|giv[101]	coref	13-25
13-4	2026-2036	production	abstract[101]	giv[101]	_	_
13-5	2037-2040	can	_	_	_	_
13-6	2041-2043	be	_	_	_	_
13-7	2044-2049	often	_	_	_	_
13-8	2050-2059	increased	_	_	_	_
13-9	2060-2067	through	_	_	_	_
13-10	2068-2081	psychological	abstract[102]	new[102]	_	_
13-11	2082-2089	support	abstract[102]	new[102]	_	_
13-12	2090-2092	or	_	_	_	_
13-13	2093-2101	maternal	event[103]	new[103]	_	_
13-14	2102-2115	breastfeeding	event[103]	new[103]	_	_
13-15	2116-2125	education	event[103]	new[103]	_	_
13-16	2126-2127	,	_	_	_	_
13-17	2128-2132	many	person[104]	giv[104]	ana	13-24[0_104]
13-18	2133-2140	healthy	person[104]	giv[104]	_	_
13-19	2141-2148	mothers	person[104]	giv[104]	_	_
13-20	2149-2152	are	_	_	_	_
13-21	2153-2158	eager	_	_	_	_
13-22	2159-2161	to	_	_	_	_
13-23	2162-2169	enhance	_	_	_	_
13-24	2170-2175	their	person|abstract[107]	giv|giv[107]	coref|coref	21-8[162_107]|26-30
13-25	2176-2180	milk	substance|abstract[107]	giv|giv[107]	coref	20-12
13-26	2181-2191	production	abstract[107]	giv[107]	_	_
13-27	2192-2199	through	_	_	_	_
13-28	2200-2207	various	substance[108]	new[108]	_	_
13-29	2208-2219	nutritional	substance[108]	new[108]	_	_
13-30	2220-2231	supplements	substance[108]	new[108]	_	_
13-31	2232-2233	.	_	_	_	_

#Text=Several drugs and herbal preparations have traditionally been prescribed as galactologues : i. e. , substances that promote initiation or increase of lactation .
14-1	2234-2241	Several	substance[109]	new[109]	coref	15-1[116_109]
14-2	2242-2247	drugs	substance[109]	new[109]	_	_
14-3	2248-2251	and	_	_	_	_
14-4	2252-2258	herbal	object|abstract[111]	new|new[111]	_	_
14-5	2259-2271	preparations	abstract[111]	new[111]	_	_
14-6	2272-2276	have	_	_	_	_
14-7	2277-2290	traditionally	_	_	_	_
14-8	2291-2295	been	_	_	_	_
14-9	2296-2306	prescribed	_	_	_	_
14-10	2307-2309	as	_	_	_	_
14-11	2310-2323	galactologues	_	_	_	_
14-12	2324-2325	:	_	_	_	_
14-13	2326-2328	i.	_	_	_	_
14-14	2329-2331	e.	_	_	_	_
14-15	2332-2333	,	_	_	_	_
14-16	2334-2344	substances	substance	new	_	_
14-17	2345-2349	that	_	_	_	_
14-18	2350-2357	promote	_	_	_	_
14-19	2358-2368	initiation	event	new	_	_
14-20	2369-2371	or	_	_	_	_
14-21	2372-2380	increase	abstract[114]	new[114]	ana	16-1[0_114]
14-22	2381-2383	of	abstract[114]	new[114]	_	_
14-23	2384-2393	lactation	abstract[114]|event	new[114]|new	coref	16-26
14-24	2394-2395	.	_	_	_	_

#Text=Drugs like domperidone® or metoclopramide® carry the risk of adverse side effects such as arrhythmia or hypothyroidism in mother-children dyad .
15-1	2396-2401	Drugs	substance[116]	giv[116]	_	_
15-2	2402-2406	like	substance[116]	giv[116]	_	_
15-3	2407-2419	domperidone®	substance[116]|substance	giv[116]|new	_	_
15-4	2420-2422	or	substance[116]	giv[116]	_	_
15-5	2423-2438	metoclopramide®	substance[116]|substance	giv[116]|new	_	_
15-6	2439-2444	carry	_	_	_	_
15-7	2445-2448	the	abstract[119]	new[119]	_	_
15-8	2449-2453	risk	abstract[119]	new[119]	_	_
15-9	2454-2456	of	abstract[119]	new[119]	_	_
15-10	2457-2464	adverse	abstract[119]|abstract[121]	new[119]|new[121]	coref	18-20[140_121]
15-11	2465-2469	side	abstract[119]|abstract|abstract[121]	new[119]|new|new[121]	_	_
15-12	2470-2477	effects	abstract[119]|abstract[121]	new[119]|new[121]	_	_
15-13	2478-2482	such	abstract[119]|abstract[121]	new[119]|new[121]	_	_
15-14	2483-2485	as	abstract[119]|abstract[121]	new[119]|new[121]	_	_
15-15	2486-2496	arrhythmia	abstract[119]|abstract[121]|abstract	new[119]|new[121]|new	_	_
15-16	2497-2499	or	abstract[119]|abstract[121]	new[119]|new[121]	_	_
15-17	2500-2514	hypothyroidism	abstract[119]|abstract[121]|abstract[123]	new[119]|new[121]|new[123]	_	_
15-18	2515-2517	in	abstract[119]|abstract[121]|abstract[123]	new[119]|new[121]|new[123]	_	_
15-19	2518-2533	mother-children	abstract[119]|abstract[121]|abstract[123]|abstract[124]	new[119]|new[121]|new[123]|giv[124]	coref	27-12[221_124]
15-20	2534-2538	dyad	abstract[119]|abstract[121]|abstract[123]|abstract[124]	new[119]|new[121]|new[123]|giv[124]	_	_
15-21	2539-2540	.	_	_	_	_

#Text=That is why herbal galactologues like fennel , anise , barley , milk thistle , or garlic are becoming more and more popular for increasing lactation .
16-1	2541-2545	That	abstract	giv	coref	22-25[181_0]
16-2	2546-2548	is	_	_	_	_
16-3	2549-2552	why	_	_	_	_
16-4	2553-2559	herbal	substance[126]	new[126]	_	_
16-5	2560-2573	galactologues	substance[126]	new[126]	_	_
16-6	2574-2578	like	substance[126]	new[126]	_	_
16-7	2579-2585	fennel	substance[126]|plant	new[126]|new	_	_
16-8	2586-2587	,	substance[126]	new[126]	_	_
16-9	2588-2593	anise	substance[126]|plant	new[126]|new	_	_
16-10	2594-2595	,	substance[126]	new[126]	_	_
16-11	2596-2602	barley	substance[126]|plant	new[126]|new	_	_
16-12	2603-2604	,	substance[126]	new[126]	_	_
16-13	2605-2609	milk	substance[126]|plant[130]	new[126]|new[130]	_	_
16-14	2610-2617	thistle	substance[126]|plant[130]	new[126]|new[130]	_	_
16-15	2618-2619	,	substance[126]	new[126]	_	_
16-16	2620-2622	or	substance[126]	new[126]	_	_
16-17	2623-2629	garlic	substance[126]|plant	new[126]|new	_	_
16-18	2630-2633	are	_	_	_	_
16-19	2634-2642	becoming	_	_	_	_
16-20	2643-2647	more	_	_	_	_
16-21	2648-2651	and	_	_	_	_
16-22	2652-2656	more	_	_	_	_
16-23	2657-2664	popular	_	_	_	_
16-24	2665-2668	for	_	_	_	_
16-25	2669-2679	increasing	_	_	_	_
16-26	2680-2689	lactation	event	giv	coref	26-25
16-27	2690-2691	.	_	_	_	_

#Text=Among these herbal compounds , fenugreek probably is the most widely consumed .
17-1	2692-2697	Among	_	_	_	_
17-2	2698-2703	these	substance[133]	new[133]	_	_
17-3	2704-2710	herbal	substance[133]	new[133]	_	_
17-4	2711-2720	compounds	substance[133]	new[133]	_	_
17-5	2721-2722	,	_	_	_	_
17-6	2723-2732	fenugreek	substance	new	coref	18-1
17-7	2733-2741	probably	_	_	_	_
17-8	2742-2744	is	_	_	_	_
17-9	2745-2748	the	_	_	_	_
17-10	2749-2753	most	_	_	_	_
17-11	2754-2760	widely	_	_	_	_
17-12	2761-2769	consumed	_	_	_	_
17-13	2770-2771	.	_	_	_	_

#Text=Fenugreek has been used since antiquity in traditional Persian , Chinese , and Egyptian medicine for its range of therapeutic effects .
18-1	2772-2781	Fenugreek	substance	giv	ana	19-1
18-2	2782-2785	has	_	_	_	_
18-3	2786-2790	been	_	_	_	_
18-4	2791-2795	used	_	_	_	_
18-5	2796-2801	since	_	_	_	_
18-6	2802-2811	antiquity	time[136]	new[136]	_	_
18-7	2812-2814	in	time[136]	new[136]	_	_
18-8	2815-2826	traditional	time[136]|abstract[137]	new[136]|new[137]	ana	18-17[0_137]
18-9	2827-2834	Persian	time[136]|abstract[137]	new[136]|new[137]	_	_
18-10	2835-2836	,	time[136]|abstract[137]	new[136]|new[137]	_	_
18-11	2837-2844	Chinese	time[136]|abstract[137]	new[136]|new[137]	_	_
18-12	2845-2846	,	time[136]|abstract[137]	new[136]|new[137]	_	_
18-13	2847-2850	and	time[136]|abstract[137]	new[136]|new[137]	_	_
18-14	2851-2859	Egyptian	time[136]|abstract[137]	new[136]|new[137]	_	_
18-15	2860-2868	medicine	time[136]|abstract[137]	new[136]|new[137]	_	_
18-16	2869-2872	for	_	_	_	_
18-17	2873-2876	its	abstract|abstract[139]	giv|new[139]	ana	20-9[0_139]
18-18	2877-2882	range	abstract[139]	new[139]	_	_
18-19	2883-2885	of	abstract[139]	new[139]	_	_
18-20	2886-2897	therapeutic	abstract[139]|abstract[140]	new[139]|giv[140]	coref	19-10[144_140]
18-21	2898-2905	effects	abstract[139]|abstract[140]	new[139]|giv[140]	_	_
18-22	2906-2907	.	_	_	_	_

#Text=It is now increasingly consumed in Western countries for its presumed protective effects against diabetes , atherosclerosis , inflammation , and hypertriglyceridemia , as well as its putative role as a galactologue due , in part , to trigonelline , one of its main active ingredients .
19-1	2908-2910	It	substance	giv	ana	19-10
19-2	2911-2913	is	_	_	_	_
19-3	2914-2917	now	_	_	_	_
19-4	2918-2930	increasingly	_	_	_	_
19-5	2931-2939	consumed	_	_	_	_
19-6	2940-2942	in	_	_	_	_
19-7	2943-2950	Western	place[142]	giv[142]	_	_
19-8	2951-2960	countries	place[142]	giv[142]	_	_
19-9	2961-2964	for	place[142]	giv[142]	_	_
19-10	2965-2968	its	place[142]|substance|abstract[144]	giv[142]|giv|giv[144]	ana	19-27
19-11	2969-2977	presumed	place[142]|abstract[144]	giv[142]|giv[144]	_	_
19-12	2978-2988	protective	place[142]|abstract[144]	giv[142]|giv[144]	_	_
19-13	2989-2996	effects	place[142]|abstract[144]	giv[142]|giv[144]	_	_
19-14	2997-3004	against	place[142]|abstract[144]	giv[142]|giv[144]	_	_
19-15	3005-3013	diabetes	place[142]|abstract[144]|abstract[145]	giv[142]|giv[144]|giv[145]	_	_
19-16	3014-3015	,	place[142]|abstract[144]|abstract[145]	giv[142]|giv[144]|giv[145]	_	_
19-17	3016-3031	atherosclerosis	place[142]|abstract[144]|abstract[145]|abstract	giv[142]|giv[144]|giv[145]|new	_	_
19-18	3032-3033	,	place[142]|abstract[144]|abstract[145]	giv[142]|giv[144]|giv[145]	_	_
19-19	3034-3046	inflammation	place[142]|abstract[144]|abstract[145]|abstract	giv[142]|giv[144]|giv[145]|new	_	_
19-20	3047-3048	,	place[142]|abstract[144]|abstract[145]	giv[142]|giv[144]|giv[145]	_	_
19-21	3049-3052	and	place[142]|abstract[144]|abstract[145]	giv[142]|giv[144]|giv[145]	_	_
19-22	3053-3073	hypertriglyceridemia	place[142]|abstract[144]|abstract[145]|abstract	giv[142]|giv[144]|giv[145]|new	_	_
19-23	3074-3075	,	place[142]|abstract[144]|abstract[145]	giv[142]|giv[144]|giv[145]	_	_
19-24	3076-3078	as	place[142]|abstract[144]|abstract[145]	giv[142]|giv[144]|giv[145]	_	_
19-25	3079-3083	well	place[142]|abstract[144]|abstract[145]	giv[142]|giv[144]|giv[145]	_	_
19-26	3084-3086	as	place[142]|abstract[144]|abstract[145]	giv[142]|giv[144]|giv[145]	_	_
19-27	3087-3090	its	place[142]|abstract[144]|abstract[145]|substance|abstract[150]	giv[142]|giv[144]|giv[145]|giv|new[150]	ana	19-43
19-28	3091-3099	putative	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-29	3100-3104	role	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-30	3105-3107	as	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-31	3108-3109	a	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-32	3110-3122	galactologue	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-33	3123-3126	due	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-34	3127-3128	,	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-35	3129-3131	in	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-36	3132-3136	part	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-37	3137-3138	,	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-38	3139-3141	to	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-39	3142-3154	trigonelline	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-40	3155-3156	,	place[142]|abstract[144]|abstract[145]|abstract[150]	giv[142]|giv[144]|giv[145]|new[150]	_	_
19-41	3157-3160	one	place[142]|abstract[144]|abstract[145]|abstract[150]|object[151]	giv[142]|giv[144]|giv[145]|new[150]|new[151]	_	_
19-42	3161-3163	of	place[142]|abstract[144]|abstract[145]|abstract[150]|object[151]	giv[142]|giv[144]|giv[145]|new[150]|new[151]	_	_
19-43	3164-3167	its	place[142]|abstract[144]|abstract[145]|abstract[150]|object[151]|substance|substance[153]	giv[142]|giv[144]|giv[145]|new[150]|new[151]|giv|new[153]	coref	21-6[160_0]
19-44	3168-3172	main	place[142]|abstract[144]|abstract[145]|abstract[150]|object[151]|substance[153]	giv[142]|giv[144]|giv[145]|new[150]|new[151]|new[153]	_	_
19-45	3173-3179	active	place[142]|abstract[144]|abstract[145]|abstract[150]|object[151]|substance[153]	giv[142]|giv[144]|giv[145]|new[150]|new[151]|new[153]	_	_
19-46	3180-3191	ingredients	place[142]|abstract[144]|abstract[145]|abstract[150]|object[151]|substance[153]	giv[142]|giv[144]|giv[145]|new[150]|new[151]|new[153]	_	_
19-47	3192-3193	.	_	_	_	_

#Text=There is , however , little evidence for its effectiveness on milk yield .
20-1	3194-3199	There	_	_	_	_
20-2	3200-3202	is	_	_	_	_
20-3	3203-3204	,	_	_	_	_
20-4	3205-3212	however	abstract[154]	new[154]	_	_
20-5	3213-3214	,	abstract[154]	new[154]	_	_
20-6	3215-3221	little	abstract[154]	new[154]	_	_
20-7	3222-3230	evidence	abstract[154]	new[154]	_	_
20-8	3231-3234	for	abstract[154]	new[154]	_	_
20-9	3235-3238	its	abstract[154]|abstract|abstract[156]	new[154]|giv|new[156]	coref	26-6[204_156]
20-10	3239-3252	effectiveness	abstract[154]|abstract[156]	new[154]|new[156]	_	_
20-11	3253-3255	on	abstract[154]|abstract[156]	new[154]|new[156]	_	_
20-12	3256-3260	milk	abstract[154]|abstract[156]|substance|abstract[158]	new[154]|new[156]|giv|new[158]	coref	21-8
20-13	3261-3266	yield	abstract[154]|abstract[156]|abstract[158]	new[154]|new[156]|new[158]	_	_
20-14	3267-3268	.	_	_	_	_

#Text=Whereas a positive effect of fenugreek on milk production was observed in various mammals , such as rabbit , buffalo , goat , or ewe ; the wide range of doses tested ( from 180 mg .
21-1	3269-3276	Whereas	_	_	_	_
21-2	3277-3278	a	abstract[159]	new[159]	coref	22-16[177_159]
21-3	3279-3287	positive	abstract[159]	new[159]	_	_
21-4	3288-3294	effect	abstract[159]	new[159]	_	_
21-5	3295-3297	of	abstract[159]	new[159]	_	_
21-6	3298-3307	fenugreek	abstract[159]|substance[160]	new[159]|giv[160]	coref	22-46[0_160]
21-7	3308-3310	on	abstract[159]|substance[160]	new[159]|giv[160]	_	_
21-8	3311-3315	milk	abstract[159]|substance[160]|substance|abstract[162]	new[159]|giv[160]|giv|giv[162]	coref|coref	22-20|22-20[179_162]
21-9	3316-3326	production	abstract[159]|substance[160]|abstract[162]	new[159]|giv[160]|giv[162]	_	_
21-10	3327-3330	was	_	_	_	_
21-11	3331-3339	observed	_	_	_	_
21-12	3340-3342	in	_	_	_	_
21-13	3343-3350	various	animal[163]	new[163]	_	_
21-14	3351-3358	mammals	animal[163]	new[163]	_	_
21-15	3359-3360	,	animal[163]	new[163]	_	_
21-16	3361-3365	such	animal[163]	new[163]	_	_
21-17	3366-3368	as	animal[163]	new[163]	_	_
21-18	3369-3375	rabbit	animal[163]|animal	new[163]|new	coref	24-20
21-19	3376-3377	,	animal[163]	new[163]	_	_
21-20	3378-3385	buffalo	animal[163]|animal	new[163]|new	_	_
21-21	3386-3387	,	animal[163]	new[163]	_	_
21-22	3388-3392	goat	animal[163]|animal	new[163]|new	_	_
21-23	3393-3394	,	animal[163]	new[163]	_	_
21-24	3395-3397	or	animal[163]	new[163]	_	_
21-25	3398-3401	ewe	animal[163]|animal	new[163]|new	_	_
21-26	3402-3403	;	animal[163]	new[163]	_	_
21-27	3404-3407	the	animal[163]|quantity[168]	new[163]|new[168]	_	_
21-28	3408-3412	wide	animal[163]|quantity[168]	new[163]|new[168]	_	_
21-29	3413-3418	range	animal[163]|quantity[168]	new[163]|new[168]	_	_
21-30	3419-3421	of	animal[163]|quantity[168]	new[163]|new[168]	_	_
21-31	3422-3427	doses	animal[163]|quantity[168]|quantity	new[163]|new[168]|new	_	_
21-32	3428-3434	tested	_	_	_	_
21-33	3435-3436	(	_	_	_	_
21-34	3437-3441	from	_	_	_	_
21-35	3442-3445	180	quantity[170]	new[170]	_	_
21-36	3446-3448	mg	quantity[170]	new[170]	_	_
21-37	3449-3450	.	_	_	_	_

#Text=kg-1 . d-1 to 2.1 g. kg-1 . d-1 ) led to large discrepancies in the reported effect on milk production ( ranging from a 10 % increase to a 110 % increase ) , which makes it difficult to determine the effective dose of fenugreek .
22-1	3451-3455	kg-1	substance	new	coref	22-5[174_0]
22-2	3456-3457	.	_	_	_	_
22-3	3458-3461	d-1	quantity[172]	new[172]	appos	22-9[0_172]
22-4	3462-3464	to	quantity[172]	new[172]	_	_
22-5	3465-3468	2.1	quantity[172]|substance[174]	new[172]|giv[174]	_	_
22-6	3469-3471	g.	quantity[172]|quantity|substance[174]	new[172]|new|giv[174]	_	_
22-7	3472-3476	kg-1	quantity[172]|substance[174]	new[172]|giv[174]	_	_
22-8	3477-3478	.	_	_	_	_
22-9	3479-3482	d-1	quantity	giv	ana	22-38
22-10	3483-3484	)	_	_	_	_
22-11	3485-3488	led	_	_	_	_
22-12	3489-3491	to	_	_	_	_
22-13	3492-3497	large	abstract[176]	new[176]	_	_
22-14	3498-3511	discrepancies	abstract[176]	new[176]	_	_
22-15	3512-3514	in	abstract[176]	new[176]	_	_
22-16	3515-3518	the	abstract[176]|abstract[177]	new[176]|giv[177]	coref	23-8[187_177]
22-17	3519-3527	reported	abstract[176]|abstract[177]	new[176]|giv[177]	_	_
22-18	3528-3534	effect	abstract[176]|abstract[177]	new[176]|giv[177]	_	_
22-19	3535-3537	on	abstract[176]|abstract[177]	new[176]|giv[177]	_	_
22-20	3538-3542	milk	abstract[176]|abstract[177]|substance|abstract[179]	new[176]|giv[177]|giv|giv[179]	coref|coref	24-5|24-5[192_179]
22-21	3543-3553	production	abstract[176]|abstract[177]|abstract[179]	new[176]|giv[177]|giv[179]	_	_
22-22	3554-3555	(	_	_	_	_
22-23	3556-3563	ranging	_	_	_	_
22-24	3564-3568	from	_	_	_	_
22-25	3569-3570	a	abstract[181]	giv[181]	_	_
22-26	3571-3573	10	abstract[181]	giv[181]	_	_
22-27	3574-3575	%	quantity|abstract[181]	giv|giv[181]	coref	22-32
22-28	3576-3584	increase	abstract[181]	giv[181]	_	_
22-29	3585-3587	to	abstract[181]	giv[181]	_	_
22-30	3588-3589	a	abstract[181]	giv[181]	_	_
22-31	3590-3593	110	abstract[181]	giv[181]	_	_
22-32	3594-3595	%	abstract[181]|quantity	giv[181]|giv	_	_
22-33	3596-3604	increase	abstract[181]	giv[181]	_	_
22-34	3605-3606	)	_	_	_	_
22-35	3607-3608	,	_	_	_	_
22-36	3609-3614	which	_	_	_	_
22-37	3615-3620	makes	_	_	_	_
22-38	3621-3623	it	quantity	giv	_	_
22-39	3624-3633	difficult	_	_	_	_
22-40	3634-3636	to	_	_	_	_
22-41	3637-3646	determine	_	_	_	_
22-42	3647-3650	the	quantity[184]	new[184]	_	_
22-43	3651-3660	effective	quantity[184]	new[184]	_	_
22-44	3661-3665	dose	quantity[184]	new[184]	_	_
22-45	3666-3668	of	quantity[184]	new[184]	_	_
22-46	3669-3678	fenugreek	quantity[184]|substance	new[184]|giv	coref	26-9
22-47	3679-3680	.	_	_	_	_

#Text=Moreover , other studies failed to demonstrate an effect in rabbits and goats .
23-1	3681-3689	Moreover	_	_	_	_
23-2	3690-3691	,	_	_	_	_
23-3	3692-3697	other	abstract[186]	new[186]	coref	24-2[190_186]
23-4	3698-3705	studies	abstract[186]	new[186]	_	_
23-5	3706-3712	failed	_	_	_	_
23-6	3713-3715	to	_	_	_	_
23-7	3716-3727	demonstrate	_	_	_	_
23-8	3728-3730	an	abstract[187]	giv[187]	_	_
23-9	3731-3737	effect	abstract[187]	giv[187]	_	_
23-10	3738-3740	in	abstract[187]	giv[187]	_	_
23-11	3741-3748	rabbits	abstract[187]|animal	giv[187]|new	_	_
23-12	3749-3752	and	abstract[187]	giv[187]	_	_
23-13	3753-3758	goats	abstract[187]|animal	giv[187]|new	_	_
23-14	3759-3760	.	_	_	_	_

#Text=In these studies , milk production was measured either by the weight – suckle – weight method ( in rabbit ) , or by milking ( in larger animals ) .
24-1	3761-3763	In	_	_	_	_
24-2	3764-3769	these	abstract[190]	giv[190]	coref	26-3[203_190]
24-3	3770-3777	studies	abstract[190]	giv[190]	_	_
24-4	3778-3779	,	_	_	_	_
24-5	3780-3784	milk	substance|abstract[192]	giv|giv[192]	coref|coref	25-11|25-11[200_192]
24-6	3785-3795	production	abstract[192]	giv[192]	_	_
24-7	3796-3799	was	_	_	_	_
24-8	3800-3808	measured	_	_	_	_
24-9	3809-3815	either	place[193]	new[193]	coref	24-16[0_193]
24-10	3816-3818	by	place[193]	new[193]	_	_
24-11	3819-3822	the	place[193]	new[193]	_	_
24-12	3823-3829	weight	place[193]	new[193]	_	_
24-13	3830-3831	–	_	_	_	_
24-14	3832-3838	suckle	_	_	_	_
24-15	3839-3840	–	_	_	_	_
24-16	3841-3847	weight	place|abstract[195]	giv|new[195]	_	_
24-17	3848-3854	method	abstract[195]	new[195]	_	_
24-18	3855-3856	(	abstract[195]	new[195]	_	_
24-19	3857-3859	in	abstract[195]	new[195]	_	_
24-20	3860-3866	rabbit	abstract[195]|animal	new[195]|giv	_	_
24-21	3867-3868	)	abstract[195]	new[195]	_	_
24-22	3869-3870	,	_	_	_	_
24-23	3871-3873	or	_	_	_	_
24-24	3874-3876	by	_	_	_	_
24-25	3877-3884	milking	_	_	_	_
24-26	3885-3886	(	_	_	_	_
24-27	3887-3889	in	_	_	_	_
24-28	3890-3896	larger	animal[197]	new[197]	_	_
24-29	3897-3904	animals	animal[197]	new[197]	_	_
24-30	3905-3906	)	_	_	_	_
24-31	3907-3908	.	_	_	_	_

#Text=The latter methods do not , however , directly assess milk production in response to physiological suckling by the pups .
25-1	3909-3912	The	abstract[198]	new[198]	_	_
25-2	3913-3919	latter	abstract[198]	new[198]	_	_
25-3	3920-3927	methods	abstract[198]	new[198]	_	_
25-4	3928-3930	do	_	_	_	_
25-5	3931-3934	not	_	_	_	_
25-6	3935-3936	,	_	_	_	_
25-7	3937-3944	however	_	_	_	_
25-8	3945-3946	,	_	_	_	_
25-9	3947-3955	directly	_	_	_	_
25-10	3956-3962	assess	_	_	_	_
25-11	3963-3967	milk	substance|abstract[200]	giv|giv[200]	coref|coref	26-12|26-12[207_200]
25-12	3968-3978	production	abstract[200]	giv[200]	_	_
25-13	3979-3981	in	_	_	_	_
25-14	3982-3990	response	abstract[201]	new[201]	_	_
25-15	3991-3993	to	abstract[201]	new[201]	_	_
25-16	3994-4007	physiological	abstract[201]	new[201]	_	_
25-17	4008-4016	suckling	abstract[201]	new[201]	_	_
25-18	4017-4019	by	_	_	_	_
25-19	4020-4023	the	animal[202]	new[202]	_	_
25-20	4024-4028	pups	animal[202]	new[202]	_	_
25-21	4029-4030	.	_	_	_	_

#Text=Moreover , these studies evaluated the effectiveness of fenugreek to increase milk production with the aim of productivity , under otherwise optimal conditions of lactation , as opposed to mothers challenged by their perception of insufficient milk production .
26-1	4031-4039	Moreover	_	_	_	_
26-2	4040-4041	,	_	_	_	_
26-3	4042-4047	these	abstract[203]	giv[203]	coref	27-5[218_203]
26-4	4048-4055	studies	abstract[203]	giv[203]	_	_
26-5	4056-4065	evaluated	_	_	_	_
26-6	4066-4069	the	abstract[204]	giv[204]	_	_
26-7	4070-4083	effectiveness	abstract[204]	giv[204]	_	_
26-8	4084-4086	of	abstract[204]	giv[204]	_	_
26-9	4087-4096	fenugreek	abstract[204]|substance	giv[204]|giv	coref	27-15
26-10	4097-4099	to	abstract[204]	giv[204]	_	_
26-11	4100-4108	increase	abstract[204]	giv[204]	_	_
26-12	4109-4113	milk	abstract[204]|substance|abstract[207]	giv[204]|giv|giv[207]	coref|coref	26-37|26-36[216_207]
26-13	4114-4124	production	abstract[204]|abstract[207]	giv[204]|giv[207]	_	_
26-14	4125-4129	with	abstract[204]|abstract[207]	giv[204]|giv[207]	_	_
26-15	4130-4133	the	abstract[204]|abstract[207]|abstract[208]	giv[204]|giv[207]|giv[208]	_	_
26-16	4134-4137	aim	abstract[204]|abstract[207]|abstract[208]	giv[204]|giv[207]|giv[208]	_	_
26-17	4138-4140	of	abstract[204]|abstract[207]|abstract[208]	giv[204]|giv[207]|giv[208]	_	_
26-18	4141-4153	productivity	abstract[204]|abstract[207]|abstract[208]|abstract	giv[204]|giv[207]|giv[208]|new	_	_
26-19	4154-4155	,	abstract[204]	giv[204]	_	_
26-20	4156-4161	under	abstract[204]	giv[204]	_	_
26-21	4162-4171	otherwise	abstract[204]|abstract[210]	giv[204]|new[210]	_	_
26-22	4172-4179	optimal	abstract[204]|abstract[210]	giv[204]|new[210]	_	_
26-23	4180-4190	conditions	abstract[204]|abstract[210]	giv[204]|new[210]	_	_
26-24	4191-4193	of	abstract[204]|abstract[210]	giv[204]|new[210]	_	_
26-25	4194-4203	lactation	abstract[204]|abstract[210]|event	giv[204]|new[210]|giv	_	_
26-26	4204-4205	,	_	_	_	_
26-27	4206-4208	as	_	_	_	_
26-28	4209-4216	opposed	_	_	_	_
26-29	4217-4219	to	_	_	_	_
26-30	4220-4227	mothers	person	giv	ana	26-33
26-31	4228-4238	challenged	_	_	_	_
26-32	4239-4241	by	_	_	_	_
26-33	4242-4247	their	person|abstract[214]	giv|new[214]	_	_
26-34	4248-4258	perception	abstract[214]	new[214]	_	_
26-35	4259-4261	of	abstract[214]	new[214]	_	_
26-36	4262-4274	insufficient	abstract[214]|abstract[216]	new[214]|giv[216]	coref	28-9[227_216]
26-37	4275-4279	milk	abstract[214]|substance|abstract[216]	new[214]|giv|giv[216]	coref	28-9
26-38	4280-4290	production	abstract[214]|abstract[216]	new[214]|giv[216]	_	_
26-39	4291-4292	.	_	_	_	_

#Text=Finally , none of these studies evaluated the metabolic status of mother-infant dyad following fenugreek supplementation .
27-1	4293-4300	Finally	_	_	_	_
27-2	4301-4302	,	_	_	_	_
27-3	4303-4307	none	abstract[217]	new[217]	_	_
27-4	4308-4310	of	abstract[217]	new[217]	_	_
27-5	4311-4316	these	abstract[217]|abstract[218]	new[217]|giv[218]	_	_
27-6	4317-4324	studies	abstract[217]|abstract[218]	new[217]|giv[218]	_	_
27-7	4325-4334	evaluated	_	_	_	_
27-8	4335-4338	the	abstract[220]	new[220]	_	_
27-9	4339-4348	metabolic	person|abstract[220]	new|new[220]	_	_
27-10	4349-4355	status	abstract[220]	new[220]	_	_
27-11	4356-4358	of	abstract[220]	new[220]	_	_
27-12	4359-4372	mother-infant	abstract[220]|abstract[221]	new[220]|giv[221]	_	_
27-13	4373-4377	dyad	abstract[220]|abstract[221]	new[220]|giv[221]	_	_
27-14	4378-4387	following	_	_	_	_
27-15	4388-4397	fenugreek	substance|substance[223]	giv|new[223]	coref	28-7[225_0]
27-16	4398-4413	supplementation	substance[223]	new[223]	_	_
27-17	4414-4415	.	_	_	_	_

#Text=Thus , the true efficacy of fenugreek on milk production in an animal model submitted to a breastfeeding challenge remains to be ascertained .
28-1	4416-4420	Thus	_	_	_	_
28-2	4421-4422	,	_	_	_	_
28-3	4423-4426	the	abstract[224]	new[224]	_	_
28-4	4427-4431	true	abstract[224]	new[224]	_	_
28-5	4432-4440	efficacy	abstract[224]	new[224]	_	_
28-6	4441-4443	of	abstract[224]	new[224]	_	_
28-7	4444-4453	fenugreek	abstract[224]|substance[225]	new[224]|giv[225]	_	_
28-8	4454-4456	on	abstract[224]|substance[225]	new[224]|giv[225]	_	_
28-9	4457-4461	milk	abstract[224]|substance[225]|substance|abstract[227]	new[224]|giv[225]|giv|giv[227]	_	_
28-10	4462-4472	production	abstract[224]|substance[225]|abstract[227]	new[224]|giv[225]|giv[227]	_	_
28-11	4473-4475	in	abstract[224]	new[224]	_	_
28-12	4476-4478	an	abstract[224]|abstract[229]	new[224]|new[229]	_	_
28-13	4479-4485	animal	abstract[224]|person|abstract[229]	new[224]|new|new[229]	_	_
28-14	4486-4491	model	abstract[224]|abstract[229]	new[224]|new[229]	_	_
28-15	4492-4501	submitted	_	_	_	_
28-16	4502-4504	to	_	_	_	_
28-17	4505-4506	a	event[230]	new[230]	_	_
28-18	4507-4520	breastfeeding	event[230]	new[230]	_	_
28-19	4521-4530	challenge	event[230]	new[230]	_	_
28-20	4531-4538	remains	_	_	_	_
28-21	4539-4541	to	_	_	_	_
28-22	4542-4544	be	_	_	_	_
28-23	4545-4556	ascertained	_	_	_	_
28-24	4557-4558	.	_	_	_	_
